Osimertinib

The FDA approved osimertinib as adjuvant therapy for patients with non-small cell lung cancer with EGFR mutations.

The FDA granted priority review to osimertinib for adjuvant treatment of certain patients with early-stage non-small cell lung cancer.

In this video, Jyoti D. Patel, MD, associate vice chair for clinical research and professor of medicine at Northwestern’s Feinberg School of Medicine, discussed two presentations from the ESMO Virtual Congress 2020.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, discussed findings from the ADAURA trial presented at ESMO Virtual Congress 2020.

Adjuvant osimertinib induced clinically meaningful reductions in central nervous system disease recurrence and death among patients with EGFR-mutated non-small cell lung cancer, according to data presented at the ESMO Virtual Congress 2020.

The FDA today approved Guardant360 CDx, a liquid biopsy companion diagnostic that uses next-generation sequencing, to identify EGFR mutations in patients with metastatic non-small cell lung cancer.

The FDA has granted breakthrough therapy designation to osimertinib for certain patients with early-stage non-small cell lung cancer. It was the top story in hematology/oncology last week.

The FDA granted breakthrough therapy designation to osimertinib for adjuvant treatment of certain patients with early-stage non-small cell lung cancer, according to the agent’s manufacturer.

In the first-line setting, osimertinib and gefitinib as combination therapy for the treatment of EGFR-mutated non-small cell lung cancer is tolerable, according to findings presented at the virtual ASCO annual meeting.

Among patients with non-small cell lung cancer who harbor MET exon 14 skipping mutations, or METex14+, savolitinib demonstrated tolerability and anti-tumor activity, according to findings from a phase 2 study presented at the virtual ASCO annual meeting.